TrialJournal for immunotherapy of cancer2020

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.

Julie N Graff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.